stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Book value per share
Takeda Pharmaceutical Co.'s book value per share at the end of fiscal 2026 was 15.6×, up 7.39% from 14.5× in fiscal 2025. At the end of the quarter to 30 September 2026 it was 0.0×. Over the past ten years it has ranged from 10.6× (fiscal 2016) to 24.2× (fiscal 2019); the current reading is higher than 67% of that period. Takeda Pharmaceutical Co. ranks 58th of 84 Drug Manufacturers Specialty & Generic companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2026 | 15.6× | 7.39% |
| FY2025 | 14.5× | (9.63%) |
| FY2024 | 16.0× | 5.87% |
| FY2023 | 15.2× | (6.34%) |
| FY2022 | 16.2× | 3.84% |
| FY2021 | 15.6× | 11.55% |
| FY2020 | 14.0× | (42.21%) |
| FY2019 | 24.2× | 107.86% |
| FY2018 | 11.6× | 0.21% |
| FY2017 | 11.6× | 8.98% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 15.1× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 30 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| UTHR United Therapeutics Corporation compare | 147× |
| NBIX Neurocrine Biosciences, Inc. compare | 38.2× |
| ELAN Elanco Animal Health Incorporated compare | 13.2× |
| ZTS Zoetis Inc. compare | 7.5× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 6.8× |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.9× |
| TAK Takeda Pharmaceutical Co. | 0.0× |
| HLN Haleon PLC Sponsored ADR compare | 0.0× |
| VTRS Viatris Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement